Antipruritic Market- By Drug , By Route of Administration , By Application , By Distribution Channel and By Geography - Opportunity Analysis & Industry Forecast, 2025-2031.

 Antipruritic Market Overview

The Antipruritic Market size is estimated to reach $14.3 Billion by 2031, growing at a CAGR of 5.4% during the forecast period 2025-2031. The antipruritic market encompasses products designed to alleviate itching (pruritus) caused by various dermatological conditions, including atopic dermatitis, eczema, psoriasis and allergic reactions. This market includes topical treatments such as creams, ointments and lotions as well as oral medications like antihistamines and corticosteroids, aimed at reducing discomfort and inflammation. The growth of the antipruritic market is primarily driven by the increasing prevalence of skin conditions worldwide, the growing awareness of these disorders and advancements in treatment options. Additionally, the rising demand for over-the-counter (OTC) products, which are more accessible and affordable, is boosting market expansion. The psychosocial impact of chronic pruritus which significantly affects patients' quality of life is another key factor pushing the demand for effective treatments. Additionally, stress-induced flare-ups of skin conditions have added to the demand for antipruritic solutions, accelerating market expansion.

The shift toward biologics in the anti-pruritic market reflects a growing trend as unlike traditional treatments, which often provide temporary relief or have broad mechanisms of action, biologics specifically target immune pathways involved in inflammation and itching. For example in December 2024, the U.S. Food and Drug Administration (FDA) granted approval for Nemolizumab as a treatment for moderate-to-severe atopic dermatitis in patients aged 12 years and older, specifically in those whose condition has not been adequately controlled with topical therapies. Similarly, dupilumab, which inhibits the IL-4 and IL-13 receptors, is already licensed and widely used for treating moderate to severe AD. Other biologic drugs, such as EP262, abrocitinib, and upadacitinib, are also in advanced clinical trials, highlighting the expansion of biologic therapies in the market. Additionally, the trend of alternative to pharmacological treatments in the anti-pruritic market highlights the growing interest in non-invasive, non-drug therapies to manage conditions like pruritus. One prominent example is UV-B therapy, which is commonly used in combination with physical therapy to treat pruritus, particularly for conditions such as eczema and psoriasis. UV-B light works by reducing cutaneous phosphorus, lowering the number of dermal mast cells, and reducing epidermal vitamin A levels, leading to significant symptom relief and even months of remission after just 6-8 treatments. Despite these concerns, the growing use of UV-B therapy and other non-pharmacological treatments reflects the demand for alternative approaches that provide relief without the side effects associated with long-term pharmacological treatments, offering patients more options for managing chronic pruritus.

Market Snapshot: 

Antipruritic Market- Report Coverage:

The “Antipruritic Market Report - Forecast (2025-2031)” by IndustryARC, covers an in-depth analysis of the following segments in the

COVID-19 / Ukraine Crisis - Impact Analysis:  

The COVID-19 pandemic led to disruptions in healthcare systems worldwide, with lockdowns, restrictions on travel, and social distancing measures. Dermatology clinics and hospitals saw reduced patient footfall due to these factors, and elective treatments, including those for chronic skin conditions like eczema and psoriasis, were postponed. This disruption resulted in a temporary decline in demand for medical antipruritic treatments, such as prescription creams and biologics, as many patients were unable to access dermatology services. Additionally, the focus on treating COVID-19 cases in healthcare settings diverted attention from other medical concerns, further affecting the market.

The Russia-Ukraine conflict led to increased uncertainty in various sectors, including the healthcare industry. Raw materials and active pharmaceutical ingredients (APIs) used in the production of antipruritic treatments have faced supply chain bottlenecks, as both Russia and Ukraine are key suppliers for certain chemicals and materials. These disruptions have resulted in delays, price hikes, and shortages of some pharmaceutical products, which could affect the availability and cost of antipruritic treatments in affected regions. Furthermore, the war has contributed to inflation and economic hardships, potentially limiting consumers' ability to afford healthcare services or medications, particularly in Eastern Europe and neighboring countries.

Key Takeaways:

• North America is Leading the Market:

North America accounted for largest market share in 2024 driven by a combination of strong healthcare infrastructure, significant investments and a growing focus on biologic therapies. The region's dominance is expected to continue due to its robust pharmaceutical industry, which is increasingly focused on developing innovative and effective treatments for chronic pruritic conditions. In May 2024, CPHI North America, one of the largest events in the Americas for the pharmaceutical industry, reported that investment returns and biologics are poised for high growth in the second half of 2024. The event saw a 16% increase in critical buyer attendees, reflecting the growing interest in biologics and their applications in treating conditions like atopic dermatitis and psoriasis. With over 4,000 participants and 370+ exhibitors, the event highlighted the expanding role of North American companies in supporting bioproduction needs. Notably, the bioproduction area was set to expand to over 50 exhibitors, underscoring the increasing capacity for biologic drug manufacturing in the region. Additionally, in June 2024, Kyowa Kirin Inc. announced a significant investment of up to $530 million to build a 171,700-square-foot facility in Sanford, North Carolina, aimed at accelerating the development and production of biologic therapies for rare and serious diseases. This major investment reflects the region’s strategic efforts to strengthen its position in the global biologics market and meet the rising demand for targeted, effective treatments for chronic pruritus and other dermatological conditions. North America's leadership in biologics development, supported by ongoing investments, plays a key role in maintaining its dominance in the anti-pruritic market.

• Dermatitis is the largest segment

Dermatitis, particularly atopic dermatitis (AD), leads the market due to the high prevalence of the condition and the significant impact it has on patients' lives. According to a December 2024 article from  National Eczema Association, atopic dermatitis affects more than 230 million people worldwide, including approximately 7% of people in the U.S. AD is often reported as one of the most problematic conditions, with 87% of patients seeking relief from the itch that is a hallmark of the disease. The urgency for rapid itch relief is a priority for both patients and physicians, making effective treatments for AD a key focus within the anti-pruritic market. The disease itself is highly heterogeneous and often associated with comorbid conditions, such as mental health disorders and other immune-mediated diseases, further driving the need for targeted and comprehensive treatment approaches. Moreover, in December 2024, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union. This highlights the ongoing progress in biologic treatments for dermatitis, specifically those targeting the immune system's role in inflammation and itching, and reinforces the strong market focus on dermatitis-related applications in the anti-pruritic space. As the demand for faster and more effective treatments grows, especially for chronic and severe forms of dermatitis, the market for dermatitis therapies is expected to continue its leadership in the anti-pruritic segment.

• Stress-Induced Skin Conditions to Drive the Market

Stress-induced skin conditions are fueling significant opportunities in the antipruritic market, as stress is increasingly recognized as a major trigger for conditions like atopic dermatitis (AD), eczema, and other skin-related disorders. As per the 2022 global report by the Eczema Council , atopic dermatitis has a high prevalence, affecting up to 20% of children and 10% of adults worldwide. The burden of the disease is significant, ranking 15th globally for non-fatal diseases and being the most prevalent skin disease. The severity of itch associated with atopic dermatitis often leads to repeated scratching, which can result in further skin damage, exacerbating the condition. This trend is closely linked to stress, which is known to exacerbate flare-ups of AD and other skin conditions. In light of this, companies like Almirall have launched awareness campaigns such as the ‘Moving aheAD’ initiative, unveiled on World Atopic Eczema Day (14 September 2023), to raise awareness about the impact of atopic dermatitis and its connection to stress. This growing awareness of the role of stress in exacerbating skin conditions presents a major opportunity for the market to develop innovative treatments and stress-management therapies that address both the physical and psychological aspects of these conditions. The increasing focus on stress-related triggers is driving demand for holistic and integrated treatment approaches, further expanding the anti-pruritic market and offering new growth avenues for companies targeting stress-induced skin conditions.

• Regulatory changes and transparency

Regulatory changes and transparency are becoming increasingly important particularly as regulatory bodies work to ensure clearer, more accurate labeling and better communication of ingredient information to healthcare professionals and patients. A significant example of this trend is a 2023 article from tga.gov.au, which announced that, moving forward, labels on medicinal products will need to reflect only the new ingredient name for most active ingredients. This change is part of a broader effort to enhance transparency and standardization in the pharmaceutical industry, making it easier for both patients and healthcare providers to understand the ingredients in the medications they are using.Under these new regulations, medicine sponsors have a window of the next three years to remove outdated ingredient names from their product labels. This also extends to updating associated Product Information and Consumer Medicines Information (CMI) documents to reflect the changes. For ingredients like alimemazine (also known as Panectyl, an antipruritic used to relieve itching), the new and old names will be displayed indefinitely. This dual-display system ensures a smooth transition for existing users of the medication while enhancing clarity for future patients and healthcare professionals.These regulatory changes aim to improve safety, reduce confusion, and promote better communication, ensuring that patients can make more informed decisions about the medications they use for conditions like pruritus.

For more details on this report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in The Speech-to-Speech Translation Market. The top 10 companies in this industry are listed below:

1. Eli Lilly and Company
2. Galderma SA
3. Pfizer Inc.
4. Amgen Inc.
5. AbbVie Inc.
6. Novartis AG
7. Sanofi S.A
8. Johnson & Johnson
9. LEO Pharma
10. Incyte

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here